Literature DB >> 23876509

CD34 affinity pheresis attenuates a surge among circulating progenitor cells following vascular injury.

Adriana Harbuzariu1, Justine Kim2, E Michael Meyer3, Albert D Donnenberg4, Bryan W Tillman5.   

Abstract

BACKGROUND: Intimal hyperplasia (restenosis) is an exaggerated healing response leading to failure of half of vascular interventions. Increasing evidence suggests that circulating progenitor cells contribute to intimal pathology, and clinical studies have demonstrated a correlation between progenitor cells and the incidence of restenosis after cardiovascular interventions. The aims of this study were to characterize the temporal response of CD34+ progenitors following vascular injury in an ovine model and to evaluate an affinity pheresis approach to attenuate this response.
METHODS: An ovine model underwent either operative vascular injury or a nonvascular surgery (n = 3 per group). Blood was examined perioperatively over 2 weeks by flow cytometry. Next, an affinity pheresis approach to mediate systemic depletion of CD34 progenitors was designed. Custom agarose pheresis matrix with antibody affinity toward CD34 or an isotype control was evaluated in vitro. Next, following vascular injury, sheep underwent perioperative whole blood volume pheresis toward either the progenitor cell marker CD34 (n = 3) or an isotype control (n = 4) for 14 days. Animals were monitored by physical exam as well as complete blood counts. Cells recovered by pheresis were eluted and examined by flow cytometry.
RESULTS: Flow cytometry revealed a focal surge of circulating CD34 cells after vascular injury but not among surgical controls (P = .05). Toward the goal of an approach to attenuate the surge of CD34 progenitors, an evaluation of high-flow affinity matrix revealed efficacy in removal of progenitors from ovine blood in vitro. Next, a separate group of animals undergoing affinity pheresis after vascular injury was evaluated to mediate systemic depletion of CD34+ cells. Again, a surge of CD34+ cells was observed among isotype pheresis animals following vascular intervention but was attenuated over 20-fold by a CD34 pheresis approach (P = .029). Furthermore, an average of 77 million CD34-positive cells were eluted from the CD34 pheresis matrix. Despite multiple sessions of pheresis, complete blood counts remained essentially unchanged over 2 weeks.
CONCLUSIONS: Despite evidence suggesting a role for CD34+ circulating progenitor cells in restenotic pathology, the temporal pattern of CD34 progenitors after vascular injury has not been previously defined. We have demonstrated a surge among circulating CD34+ cells that appears confined to procedures involving vascular injury and that this event seems to occur early after vascular injury. We further conclude that CD34 affinity pheresis attenuates the surge. This approach for direct depletion of progenitors may have important implications for the study of progenitors in vascular restenosis.
Copyright © 2014 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23876509      PMCID: PMC4165083          DOI: 10.1016/j.jvs.2013.05.043

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  37 in total

1.  Circulating bone marrow cells can contribute to neointimal formation.

Authors:  C I Han; G R Campbell; J H Campbell
Journal:  J Vasc Res       Date:  2001 Mar-Apr       Impact factor: 1.934

2.  Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality Study.

Authors:  K D Gibson; D L Gillen; M T Caps; T R Kohler; D J Sherrard; C O Stehman-Breen
Journal:  J Vasc Surg       Date:  2001-10       Impact factor: 4.268

3.  Bioengineered vascular access maintains structural integrity in response to arteriovenous flow and repeated needle puncture.

Authors:  Bryan W Tillman; Saami K Yazdani; Lucas P Neff; Matthew A Corriere; George J Christ; Shay Soker; Anthony Atala; Randolph L Geary; James J Yoo
Journal:  J Vasc Surg       Date:  2012-09       Impact factor: 4.268

4.  Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition.

Authors:  Nikos Werner; Josef Priller; Ulrich Laufs; Matthias Endres; Michael Böhm; Ulrich Dirnagl; Georg Nickenig
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

5.  Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo.

Authors:  S Kaushal; G E Amiel; K J Guleserian; O M Shapira; T Perry; F W Sutherland; E Rabkin; A M Moran; F J Schoen; A Atala; S Soker; J Bischoff; J E Mayer
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis.

Authors:  Masataka Sata; Akio Saiura; Atsushi Kunisato; Akihiro Tojo; Seiji Okada; Takeshi Tokuhisa; Hisamaru Hirai; Masatoshi Makuuchi; Yasunobu Hirata; Ryozo Nagai
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

7.  Smooth muscle progenitor cells in human blood.

Authors:  David Simper; Paul G Stalboerger; Carmelo J Panetta; Shaohua Wang; Noel M Caplice
Journal:  Circulation       Date:  2002-09-03       Impact factor: 29.690

8.  Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries.

Authors:  Kimie Tanaka; Masataka Sata; Yasunobu Hirata; Ryozo Nagai
Journal:  Circ Res       Date:  2003-09-18       Impact factor: 17.367

9.  CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds.

Authors:  E Sivan-Loukianova; O A Awad; V Stepanovic; J Bickenbach; G C Schatteman
Journal:  J Vasc Res       Date:  2003-07-29       Impact factor: 1.934

10.  Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.

Authors:  Donald E Cutlip; Manish S Chauhan; Donald S Baim; Kalon K L Ho; Jeffrey J Popma; Joseph P Carrozza; David J Cohen; Richard E Kuntz
Journal:  J Am Coll Cardiol       Date:  2002-12-18       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.